However, clinical data on the prognostic value of LCT in patients with PD-1/PD-L1 inhibitors-treated oligo-residual NSCLC are currently scarce and should be further explored in the era of immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.